Researchers at the University of California at Irvine have claimed that an Alzheimer’s vaccine could in humans in just two years.
The researchers developed a treatment that successfully eliminated the accumulation of amyloid and tau proteins in the brains of genetically modified mice.
It is believed that these plaques trigger neurodegeneration and, ultimately, cognitive impairment.
They also suggest that this “dementia vaccine” is ready to be tested in humans, and if it is successful it could become the “breakthrough of the next decade.”
The study, published last month in the journal Alzheimer’s Research & Therapy, found that the vaccine significantly decreases the accumulations of both proteins.
The vaccine, developed by Nikolai Petrovsky, endocrinologist at the University of Flinders in Australia, combines two previous treatments, called AV-1959R and AV-1980R, respectively, designed to reduce amyloid and tau protein groups.
The vaccine is formulated in a novel adjuvant called Advax, developed by a team of Australian researchers, which improves the immunogenicity of the vaccine.
Also: THE EXERCISE VS. DEMENTIA The study found that the Alzheimer’s vaccine prevents the accumulation of proteins and eliminates those that already exist.
“We were able to prevent memory loss in mice and obviously the next step is to take this to clinical trials in humans,” Petrovsky told ABC News Australia.
He added: “It is an exciting time to start the new decade; hopefully, this is the progress of the next decade if we can make it work in human trials ».
Those tests could begin in the next 18 to 24 months, he said.
After many failures of high-profile clinical trials of drugs designed to reduce amyloid protein aggregations in the brain, some scientists are looking for vaccine-based preventive measures to combat neurodegenerative diseases such as Alzheimer’s.
Finally, the hypothesis is that avoiding the accumulation of these toxic proteins may be the most effective way to treat dementia.